Arrhythmia Research Technology, Inc.
http://www.arthrt.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arrhythmia Research Technology, Inc.
Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD
Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.
Sanofi’s Orbis-Approved GVHD Drug Rezurock Rejected For English Funding
NICE has provisionally turned down three products for funding under the National Health Service in England: Sanofi’s Rezurock for chronic graft-versus-host disease, Sobi’s lymphoma drug Zynlonta, and AstraZeneca/Daiichi Sankyo’s Enhertu for the new indication of HER2-low breast cancer.
AstraZeneca/Daiichi Sankyo’s Enhertu To Get Lung Cancer Label For EU
The European Medicines Agency has recommended new uses for 11 approved medicines, including an antibody drug conjugate for treating advanced non-small cell lung cancer.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
Company Information
- Industry
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice